Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.
The results showed that compared to placebo, GLP-1 receptor agonists reduced the risk of kidney failure by 16% and the worsening of kidney function by 22% (defined by a drop in estimated glomerular ...
GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...
GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist ...
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...
Second, Amneal has received approval from the FDA for exenatide, which is the Company’s first generic injectable glucagon-like peptide-1 (GLP-1 ... changes in kidney function, low blood sugar ...
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also ...
GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...
A new study shows GLP-1 receptor agonists offer significant protection for kidneys and heart in both diabetic and ...
New research from The George Institute of Global Health shows that a popular class of obesity and type 2 diabetes drugs can ...
The combined reduction in the risk of kidney failure, worsening kidney function and death due to kidney disease was 19%, ...